Blog

Refining the First Strike Against EGFR-Mutated Advanced NSCLC – PeerView Institute for Medical Education

PVI/LinkedIn

Nov 18, 2024, 16:59

Refining the First Strike Against EGFR-Mutated Advanced NSCLC – PeerView Institute for Medical Education

PVI (PeerView Institute for Medical Education) shared a post on LinkedIn:

“Join the lung cancer experts Drs. Stephen Liu and Zosia Piotrowska on November 22 at 9:30 AM PST during MaTOS2024 for an EGFR-mutated advanced NSCLC MedEd event.

Learners will gain case-based guidance on interpreting and applying the latest innovations effectively in practice, ensuring they are well-prepared for the frontline management of EGFR-mutated NSCLC.

This activity is supported by an independent educational grant from AstraZeneca.”

Read further.

For more posts like this, visit oncodaily.com.

AstraZeneca cancer EGFR-mutated non-small-cell lung cancer EGFR-mutated NSCLC Lung cancer MaTOS2024 MedEd OncoDaily Oncology Stephen Liu Zosia Piotrowska

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage